TheraRadar
← Back
Data updated: Sep 20, 2026

NORGINE

Pharma
OncologyGastroenterologyInfectious Disease Execution: Excellent

NORGINE is a pharmaceutical company focused on Oncology, Gastroenterology, Infectious Disease. Key products include PLENVU.

2018
Since
1
Drugs
-
Trials
0
New Drugs (2yr)
Modality:
1 Small Molecules

NORGINE at a Glance

  • Strong track record with 94% execution quality across 30 trials
  • Fast trial execution (9 months median completion)

NORGINE's Key Drugs

NORGINE's core commercial portfolio centers on PLENVU, spanning Oncology and Gastroenterology — its most strategically important drugs approved in the last 15 years.

PLENVU
Gastrointestinal

Colon cleansing in preparation for colonoscopy

Approved 2018

NORGINE's Recent FDA Approvals

New NDA/BLA approvals for NORGINE over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

NORGINE's Therapeutic Areas

NORGINE's approved drugs and pipeline span 3 therapeutic areas, led by Oncology and Gastroenterology, across 0 biologic and 1 small-molecule drug. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Oncology 67%
0 drugs Phase 3: 3 Phase 2: 2 Phase 1: 2
Gastroenterology 19%
0 drugs Phase 3: 1 Phase 1: 1
Infectious Disease 15%
0 drugs Phase 2: 2

NORGINE's Top Competitors

NORGINE's closest competitors by therapeutic-area and drug-target overlap include Johnson & Johnson, Bristol-Myers Squibb, and Pfizer. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.

Johnson & Johnson big-pharma
Oncology, Infectious Disease, Gastroenterology
Bristol-Myers Squibb big-pharma
Oncology, Infectious Disease, Gastroenterology
Pfizer big-pharma
Oncology, Infectious Disease
PF PRISM CV big-pharma
Oncology, Infectious Disease, Gastroenterology
ASTELLAS specialty
Oncology, Gastroenterology, Infectious Disease

NORGINE Pipeline Snapshot

NORGINE has 11 active clinical programs from ClinicalTrials.gov — 4 Phase 3, 4 Phase 2 and 3 Phase 1.

4
Phase 3
4
Phase 2
3
Phase 1

Phase 3 Readout Calendar Pro

1 Phase 3 trial with confidence-graded primary completion dates.

Full calendar →
Q1 2027
PLENVU®
Bowel Cleansing Prior to Clinical Procedures
Estimated · aging NCT07218523

Anchored on CT.gov primary completion date. Topline announcements typically precede this by 3–9 months. Confidence labels combine date type (ACTUAL/ESTIMATED) with last-update freshness.

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • PLENVU leads revenue
  • • Drug-level revenue analysis

Trial Catalysts

  • • Oncology pipeline focus
  • • 1 Phase 3 readout tracked
View readout calendar →

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison

Execution Intelligence

  • • Phase 3: 8/9 completed
  • • Speed: 9 months avg
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling

How We Calculate These Metrics

Execution Quality Score

Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.

What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.

  • Excellent (80%+): Top-tier execution, most trials reach planned endpoints
  • Good (60-79%): Strong execution with occasional early terminations
  • Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
  • Needs Improvement (under 40%): High termination rates, execution challenges